Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab (MONITOR)
Melanoma, Lung Cancer, Renal Cancer
About this trial
This is an interventional supportive care trial for Melanoma focused on measuring Tele-monitoring, nivolumab, ipilimumab, immunotherapy
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years
- Patients diagnosed with melanoma, or lung cancer or renal cancer
- Patients starting a treatment with a combination of immunotherapy of nivolumab + ipilimumab (NB: patients who have already received immunotherapy in the past may be included)
- Patients comfortable with the use of digital tools and computing
- Patients who agree to participate to the telemonitoring and signed consent form
Exclusion Criteria:
- Pregnant, parturient and lactating women
- Patients under legal protection measure or deprived of their liberty
- Patients not affiliated to a social security scheme (schemes such as the AME) or beneficiaries of a similar regime (foreign person, outside the EU)
Sites / Locations
- Groupement hospitalier Est - Multidisciplinary oncological platform
- Hôpital Louis Pradel - Department of Pneumology
- University hospital of Grenoble Alpes - Department of dermatology
- University hospital of Grenoble Alpes - Department of Medical Oncology
- Hôpital de la Croix Rousse - Department of Pneumology
- Hôpital Edouard Herriot - Department of urology
- Centre Hospitalier Lyon Sud - Department of Medical OncologyRecruiting
- Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer InstituteRecruiting
- Hôpital Lyon Sud - Department of pneumology,Thoracic oncologyRecruiting
- University hospital of Saint-Etienne - Department of dermatology
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Tele-monitoring group
Control group
In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12. 50 patients are expected in this arm.
In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12. 50 patients are expected in this arm.